Figure 6. Appropriate weight gain in in utero recipients of CD26-inhibited and noninhibited allogeneic BM. Chimeric BALB/c mice that had received CD26-inhibited or noninhibited BM in utero were serially weighed to assess for any deleterious effects, such as GVHD, of IUHCT. BALB/c mice that had received an in utero injection of B6GFP BM but were not chimeric postnatally were used for the control group.
Figure 6.

Appropriate weight gain in in utero recipients of CD26-inhibited and noninhibited allogeneic BM. Chimeric BALB/c mice that had received CD26-inhibited or noninhibited BM in utero were serially weighed to assess for any deleterious effects, such as GVHD, of IUHCT. BALB/c mice that had received an in utero injection of B6GFP BM but were not chimeric postnatally were used for the control group.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal